Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands

Current Medicinal Chemistry

Volumn 19, Issue 15, 2012, Pages 2343-2355

  Arsequell, G ^a   Planas, A ^b  

^a INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^b INSTITUT QUÍMIC DE SARRIÀ   (Spain)

Author keywords

Amyloid inhibitor; Amyloidosis; Drug screening; HTS; Kinetic inhibitors; Transthyretin

Indexed keywords

4' IODOESORUBICIN; AMLODIPINE; APIGENIN; CONGO RED; DICLOFENAC; DIFLUNISAL; DOXYCYCLINE; FENOPROFEN; FLUFENAMIC ACID; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; NIFLUMIC ACID; PREALBUMIN; RESVERATROL; STILBENE; SUPROFEN; THIOFLAVINE; THYROXINE; WARFARIN;

AMYLOIDOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING ASSAY; BINDING COMPETITION; BINDING SITE; BIOSENSOR; CAPILLARY ELECTROPHORESIS; CYTOTOXICITY; DROSOPHILA; EX VIVO STUDY; EXPERIMENTAL MONKEY; FLUORESCENCE ANALYSIS; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN INTERACTION; PROTEIN UNFOLDING; RADIOASSAY; SCANNING TRANSMISSION ELECTRON MICROSCOPY; STOICHIOMETRY; SURFACE PLASMON RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; TURBIDIMETRY;

EID: 84860697106     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800269281     Document Type: Article

References (157)

1. Sipe, J.D.; Benson, M.D.; Buxbaum, J.N.; Ikeda, S.; Merlini, G.; Saraiva, M.J.; Westermark, P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid, 2010, 17, 101-104.
2. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C. M.; and Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 2002, 416, 507-511. (Pubitemid 34288846)
3. Dobson, C. M. Protein folding and disease: A view from the first Horizon Symposium. Nat. Rev. Drug Discov., 2003, 2, 154-160. (Pubitemid 37361648)
4. Sacchettini, J. C.; Kelly, J. W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discov., 2002, 1, 267-275. (Pubitemid 37361443)
5. Benson, M. D. Amyloidosis. In: The Metabolic Basis of Inherited Disease, Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., Vogelstein, B., Eds.; McGraw-Hill: Columbus, Ohio. 2001; pp. 5345-5378.
6. Selkoe, D. J. Folding proteins in fatal ways. Nature, 2003, 426, 900-904. (Pubitemid 38056883)
7. Cohen, F. E.; Kelly, J.W. Therapeutic approaches to protein-misfolding diseases. Nature, 2003, 426, 905-909. (Pubitemid 38056884)
8. Johnson, S.M.; Wiseman, R.L:; Sekijima, Y.; Green, N.S.; Adamski-Werner, S.L.; Kelly, J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc. Chem. Res., 2005, 38, 911-921.
9. Saraiva, M.J. Hereditary transthyretin amyloidosis: Molecular basis and therapeutical strategies. Expert Rev. Mol. Med., 2002, 4, 1-11.
10. Saraiva, M.J. Sporadic causes of hereditary systemic amyloidosis. N. Engl. J. Med., 2002, 346, 1818-1819. (Pubitemid 34586920)
11. Connors, L.H.; Lim, A.; Prokaeva, T.; Roskens, V.A.; Costello, C.E. Tabulation of human transthyretin (TTR) variants. Amyloid, 2003, 10, 160-184. (Pubitemid 37372400)
12. Planté-Bordeneuve, V.; Said, G. Familial amyloid polyneuropathy. Lancet Neurol., 2011, 10, 1086-1097.
13. Monaco, H.L.; Rizzi, M.; Coda, A. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science, 1995, 268, 1039-1041.
14. Hamilton, J.A.; Benson, M.D. Transthyretin: A review from a structural perspective. Cell Mol. Life Sci., 2001, 58, 1491-1521. (Pubitemid 32964418)
15. Eneqvist, T.; Saur-Erikson, A.E. Structural Distribution of mutations associated with familial amyloidotic polyneuropathy in human transthyretin, Amyloid, 2001, 8, 149-168. (Pubitemid 32911602)
16. Saraiva, M.J.M. Transthyretin mutations in hyperthyroxinemia and amyloid diseases, Human Mutation, 2001, 17, 493-503. (Pubitemid 32480084)
17. Buxbaum, J.N.; Tagoe, C.E. The genetics of the amyloidoses. Annu. Rev. Med., 2000, 51, 543-569. (Pubitemid 30216054)
18. Colon, W.; Kelly, J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry, 1992, 31, 8654-8660.
19. Quintas, A.; Saraiva, M.J.; Brito, R.M. The tetrameric proteintransthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J. Biol. Chem., 1999, 274, 32943-32949. (Pubitemid 129535333)
20. Quintas, A.; Vaz, D. C.; Cardoso, I.; Saraiva, M. J.; and Brito, R. M. M. Tetramer dissociation and Monomer partial unfolding precedes protofibril formation in amyloidogenic trasnthyertin variants. J. Biol. Chem., 2001, 276, 27207-27213.
21. Cardoso, I.; Goldsbury, C. S.; Muller, S. A.; Olivieri, V.; Wirtz, S.; Damas, A. M.; Aebi, U.; Saraiva, M. J. Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for in vitro assembled tranthyretin amyloid-like fibrils. J. Mol. Biol., 2002, 317, 683-695. (Pubitemid 34722157)
22. Hurshman, A.R.; White, J.T.; Powers, E.T. Kelly; J.W. Transthyretin aggregation under partially denaturating conditions is a downhill polymerization. Biochemistry, 2004, 43, 7365-7381. (Pubitemid 38745754)
23. Sousa, M.M.; Cardoso, I.; Fernandes, R.; Guimarães, A.; Saraiva, M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of non-fibrillar aggregates. Am. J. Pathol., 2001, 159, 1993-2000. (Pubitemid 33104254)
24. Sörgjerd, K.; Klingstedt, T.; Lindgren, M.; Kagedal, K.; Hammarström, P. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem. Biophys. Res, Commun., 2008, 377, 1072-1078.
25. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol., 1998, 8, 101-106. (Pubitemid 28107921)
26. Kingsbury, J.S.; Laue, T.M.; Klimtchuk, E.S.; Théberge, R.; Costello, C.E.; Connors, L.H. The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation. J. Biol. Chem., 2008, 283, 1887-1896.
27. Quintas, A; Saraiva, M.J.; Brito, RM. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett., 1997, 418, 297-300. (Pubitemid 27515943)
28. Pilato, E.; Dell'Amore, A.; Botta, L; Arpesella, G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur. J. Cardiothorac. Surg., 2007, 32, 180-182. (Pubitemid 46874959)
29. Almeida, M.R.; Gales, L.; Damas, A.M.; Cardoso, I.; Saraiva, M.J. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr. Drug Targets CNS Neurol. Disord., 2005, 4, 587-596. (Pubitemid 41448384)
30. Connelly, S.; Choi, S.; Johnson, S.M.; Kelly, J.W.; Wilson, I.A. Structurebased design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol., 2010, 20, 54-62.
31. Ong, D.S.; Kelly, JW. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. Curr. Opin. Cell Biol., 2011, 23, 231-238.
32. Terazaki, H.; Ando, Y.; Fernandes, R.; Yamamura, K.; Maeda, S.; Saraiva, M.J. Immunization in familial amyloidotic polyneuropathy: Counteracting deposition by immunization with a Y78F TTR mutant. Lab. Invest., 2006, 86, 23-31. (Pubitemid 43250965)
33. Sekijima, Y.; Kelly, J.W.; Ikeda, S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr. Pharm. Des., 2008, 14, 3219-3230.
34. Benson, M.D.; Pandey, S.; Witchell, D.; Jazayeri, A.; Siwkowski, A.; Monia, B.; Kluve-Beckerman, B. Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid, 2011, 18 (Suppl 1), 55.
35. Benson, M.D.; Kluve-Beckerman, B.; Zeldenrust, S.R.; Siesky, A.M.; Bodenmiller, D.M.; Showalter, A.D.; Sloop, K.W. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve, 2006, 33, 609-618.
36. Nakamura, M.; Ando, Y. Applications of gene therapy for familial amyloidotic polyneuropathy. Expert Opin. Biol. Ther., 2004, 4, 1621-1627. (Pubitemid 39371757)
37. Kolstoe, S.E.; Wood, S.P. Drug targets for amyloidosis. Biochem. Soc. Trans., 2010, 38, 466-470.
38. The Effect of Diflunisal on Familial Amyloidosis: Http://clinicaltrials. gov/ct2/show/NCT00294671.
39. Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis: Http://clinicaltrials.gov/ct2/show/ NCT00409175; An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy: Http://clinicaltrials.gov/ ct2/show/NCT00791492.
40. Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis http://clinicaltrials. gov/ct2/show/NCT01171859/.
41. Renaud, J.P.; Delsuc, M.A. Biophysical techniques for ligand screening and drug design. Curr. Opin. Pharmacol., 2009, 9, 622-628.
42. Vuignier, K.; Schappler, J; Veuthey., J.L.; Carrupt, P.A.; Martel, S. Drugprotein binding: A critical review of analytical tools. Anal. Bioanal. Chem., 2010, 398, 53-66.
43. Sirangelo, I.; Irace, G. Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: Effect of tetracycline and trehalose. Expert Opin. Ther. Targets., 2010, 14, 1311-1321.
44. Palha, J.A.; Ballinari, D.; Amboldi, N.; Cardoso, I.; Fernandes, R.; Bellotti, V.; Merlini, G.; Saraiva, M.J. 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am. J. Pathol., 2000, 156, 1919-1925. (Pubitemid 30641761)
45. Lai, Z.; Colon, W.; and Kelly, J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry, 1996, 35, 6470-6482. (Pubitemid 26164080)
46. Quintas, A.; Vaz, D.C.; Cardoso, I.; Saraiva, M.J.; and Brito, R.M.M. (Tetramer dissociation and Monomer partial unfolding precedes protofibril formation in amyloidogenic trasnthyertin variants. J. Biol. Chem., 2001, 276, 27207-27213.
47. Miroy, G.J.; Lai, Z.; Lashuel, H.A.; Peterson, S.A.; Strang, C.; Kelly, J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA, 1996, 93, 15051-15056. (Pubitemid 27009550)
48. Baures, P.W; Peterson, S.A.; Kelly, J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem., 1998, 6, 1389-1401. (Pubitemid 28398970)
49. Baures, P. W.; Oza, V.B.; Peterson, S.A.; and Kelly, J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the nonsteroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem., 1999, 7, 1339-1347. (Pubitemid 29292374)
50. Klabunde, T.; Petrassi, H.M.; Oza, V.B.; Raman, P.; Kelly, J.W., Sacchettini, J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol., 2000, 7, 312-321. (Pubitemid 30194456)
51. Adamski-Werner, S.L.; Palaninathan, S.K.; Sacchettini, J.C.; Kelly, J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem., 2004, 47, 355-374. (Pubitemid 38057880)
52. Oza, V.B.; Petrassi, H.M.; Purkey, H.E.; Kelly, J.W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett., 1999, 9, 1-6. (Pubitemid 29023287)
53. Oza V.B.; Smith, C.; Raman, P.; Koepf, E.K.; Lashuel, H.A.; Petrassi, H.M.; Chiang, K.P.; Powers, E.T.; Sachettinni, J.; Kelly, J.W. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem., 2002, 45, 321-332. (Pubitemid 34073451)
54. Palaninathan, S.K.; Mohamedmohaideen, N.N.; Orlandini, E.; Ortore, G.; Nencetti, S.; Lapucci, A.; Rossello, A.; Freundlich, J.S.; Sacchettini, J.C. Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural Analysis. PLoS One, 2009, 4(7):e6290.
55. Dolado, I.; Nieto, J.; Saraiva, M. J.; Arsequell, G.; Valencia, G.; Planas, A. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J. Comb. Chem., 2005, 7, 246-252. (Pubitemid 40522007)
56. Mairal, T.; Nieto, J.; Pinto, M.; Almeida, M.R.; Gales, L.; Ballesteros, A.; Barluenga, J.; Pérez, J.J.; Vázquez, J.T.; Centeno, N.B.; Saraiva, M.J.; Damas, A.M.; Planas, A.; Arsequell, G.; Valencia, G. Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One, 2009, 4(1):e4124.
57. González, A.; Quirante, J.; Nieto, J.; Almeida, M.R.; Saraiva, M.J.; Planas, A:; Arsequell, A.; Valencia, G. Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5270-5273.
58. Blasi, D.; Arsequell, A.; Valencia, G.; Nieto, J.; Planas, A:; Pinto, M.; Centeno, N.B.; Abad-Zapatero, C.; Quintana, J. Retrospective Mapping of SAR Data for TTR Protein in Chemico-Biological Space Using Ligand Efficiency Indices as a Guide to Drug Discovery Strategies. Mol. Inf., 2011, 30, 161-167.
59. Blasi, D.; Pinto, M.; Nieto, J.; Arsequell, G.; Valencia, G.; Planas, A.; Centeno N.B.; Quintana J. Drug discovery targeted at transthyretin cardiac amyloidosis: Rational design, synthesis, and biological activity of new transthyretin amyloid inhibitors. Amyloid, 2011, 18 (Suppl 1), 50-52.
60. Pinto, M.; Blasi, D.; Nieto, J.; Arsequell, G.; Valencia, G.; Planas, A.; Quintana J.; Centeno, N.B. Ligand-binding properties of human transthyretin. Amyloid, 2011, 18 (Suppl 1), 46-49.
61. Puchtler, H.; Sweat, F. Congo red as a stain for fluorescence microscopy of amyloid. J. Histochem. Cytochem., 1965, 13, 693-694.
62. Vidal, R; Ghetti, B. Characterization of amyloid deposits in neurodegenerative diseases. Methods Mol. Biol., 2011, 793, 241-258.
63. Reinke, A.A.; Gestwicki, J.E. Insight into amyloid structure using chemical probes. Chem. Biol. Drug Des., 2011, 77, 399-411.
64. Khurana, R.; Uversky, V.N.; Nielsen, L.; Fink, A.L. Is Congo red an amyloid-specific dye? J. Biol, Chem., 2001, 276, 22715-22721.
65. Krebs, M.R.; Bromley, E.H.; Donald, A.M. The binding of thioflavin-T to amyloid fibrils: Localisation and implications. J. Struct. Biol., 2005, 149, 30-37. (Pubitemid 40051399)
66. Khurana, R.; Coleman, C.; Ionescu-Zanetti, C.; Carter, S.A.; Krishna, V.; Grover, R.K.; Roy, R.; Singh S. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol., 2005, 151, 229-238. (Pubitemid 41338730)
67. Levine, H. Thioflavine-T interaction with amyloid beta-sheet structures. Amyloid, 1995, 2, 1-6.
68. Bonifácio, M.J.; Sakaki, Y.; Saraiva, M.J. In vitro amyloid fibril formation from transthyretin: The influence of ions and the amyloidogenicity of TTR variants. Biochim. Biophys. Acta, 1996, 1316, 35-42. (Pubitemid 26173904)
69. Wilkinson-White, L.E.; Easterbrook-Smith, S.B. Characterization of the binding of Cu(II) and Zn(II) to transthyretin: Effects on amyloid formation. Biochemistry, 2007, 46, 9123-9132. (Pubitemid 47237387)
70. Hudson, S.A.; Ecroyd, H.; Kee, T.W.; Carver, J.A. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J., 2009, 276, 5960-5972.
71. Lindgren, M.; Hammarström, P. Amyloid oligomers: Spectroscopic characterization of amyloidogenic protein states. FEBS J., 2010, 277, 1380-1388.
72. Aslund, A.;Sigurdson, C.J.; Klingstedt, T.; Grathwohl, S.; Bolmont, T.; Dickstein, D.L.; Glimsdal, E.; Prokop, S.; Lindgren, M.; Konradsson, P.; Holtzman, D.M.; Hof, P.R.; Heppner, F.L.; Gandy, S.; Jucker, M.; Aguzzi, A.; Hammarström, P.; Nilsson, K.P. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. A.C.S. Chem Biol. 2009, 4, 673-684.
73. Lindgren, M.; Hammarström, P. Amyloid oligomers: Spectroscopic characterization of amyloidogenic protein states. FEBS J., 2010, 277, 1380-1388.
74. Shirahama, T.; Cohen, A. S. High resolution electron microscopic analysis of the amyloid fibril. J. Cell. Biol., 1967, 33, 679-706.
75. Goldsbury, C.; Baxa, U.; Simon, M.N.; Steven, A.C.; Engel, A.; Wall, J.S.; Aebi, U.; Müller, S.A. Amyloid structure and assembly: Insights from scanning transmission electron microscopy. J. Struct. Biol., 2011, 173, 1-13.
76. Shewmaker, F.; McGlinchey, R.P.; Wickner, R.B. Structural insights into functional and pathological amyloid. J. Biol. Chem., 2011, 286, 16533-16540.
77. Cardoso, I.; Goldsbury, C.S.; Müller, S.A.; Olivieri, V.; Wirtz, S.; Damas, A.M.; Aebi, U.; Saraiva, M.J. Transthyretin Fibrillogenesis Entails the Assembly of Monomers: A Molecular Model for in vitro Assembled Transthyretin Amyloid-like Fibrils. J. Mol. Biol., 2002, 317, 683-695 (Pubitemid 34722157)
78. Cardoso, I.; Merlini, G.; Saraiva, M.J. 4'-Iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: Screening for TTR fibril disrupters. FASEB J., 2003, 17, 803-809. (Pubitemid 36538654)
79. Pires, R.H.; Saraiva, M.J; Damas, A.M.; Kellermayer, M.S. Structure and assembly-disassembly properties of wild-type transthyretin amyloid protofibrils observed with atomic force microscopy. J. Mol. Recognit., 2011, 24, 467-476.
80. Ladbury, J.E. Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design. Biochem. Soc. Trans., 2010, 38, 888-893.
81. Peterson, S.A.; Klabunde, T.; Lashuel, H.; Purkey, H.; Sacchettini, J.C.; Kelly, J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. U S A, 1998, 95, 12956-12960. (Pubitemid 28509505)
82. Neumann, P.; Cody, V.; Wojtczak, A. Structural basis of negative cooperativity in transthyretin. Acta Biochim. Pol. 2001:867-75 (Pubitemid 33602342)
83. Wang H, Tang Y, Lei M.Models for binding cooperativities of inhibitors with transthyretin. Arch. Biochem Biophys., 2007, 466, 85-97. (Pubitemid 47405074)
84. Sørensen, J.; Hamelberg, D.; Schiøtt, B.; McCammon, J.A. Comparative MD analysis of the stability of transthyretin providing insight into the fibrillation mechanism. Biopolymers, 2007, 86, 73-82. (Pubitemid 46716696)
85. Wiseman, R.L.; Johnson, S.M.; Kelker, M.S.; Foss, T.; Wilson, I.A.; Kelly, J.W. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J. Am. Chem. Soc., 2005, 127, 5540-5551. (Pubitemid 40569865)
86. Huber, W.; Mueller, F. Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr. Pharm. Des., 2006, 12, 3999-4021. (Pubitemid 44669759)
87. Vuignier, K.; Schappler, J.; Veuthey, J.L.; Carrupt, P.A.; Martel, S. Drugprotein binding: A critical review of analytical tools. Anal. Bioanal. Chem., 2010, 398, 53-66.
88. Alhamadsheh, M.M.; Connelly, S.; Cho, A.; Reixach, N.; Powers, E.T.; Pan, D.W.; Wilson, I.A.; Kelly J.W.; Graef, I.A. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci. Transl. Med., 2011, 3, 1-9.
89. Quaglia, M; De Lorenzi E. Capillary electrophoresis in drug discovery. Methods Mol. Biol., 2009, 572, 189-202.
90. Quaglia, M.; De Lorenzi, E. In: Ligand-Macromolecule Interactions in Drug Discovery, A.C. Roque Ed.; Humana, Totowa, 2010; pp. 189-202.
91. De Lorenzi, E.; Galbusera, C.; Bellotti, V.; Mangione, P.; Massolini, G.; Tabolotti, E.; Andreola, A.; Caccialanza, G. Affinity capillary electrophoresis is a powerful tool to identify transthyretin binding drugs for potential therapeutic use in amyloidosis. Electrophoresis, 2000, 21, 3280-3289.
92. Regazzoni, L.; Colombo, R.; Bertoletti, L.; Vistoli, G.; Aldini, G.; Serra, M.; Carini, M.; Facino, R.M.; Giorgetti, S.; Stoppini, M.; Caccialanza, G.; De Lorenzi, E. Screening of fibrillogenesis inhibitors of β2-microglobulin: Integrated strategies by mass spectrometry capillary electrophoresis and in silico simulations. Anal. Chim. Acta, 2011, 685, 153-161.
93. Loo, J.A. Electrospray ionization mass spectrometry: A technology for studying noncovalent macromolecular complexes. Int. J. Mass Spectrometry, 2000, 200, 175-186. (Pubitemid 32015921)
94. Veenstra, T.D. Electrospray ionization mass spectrometry in the study of biomolecular non-covalent interactions. Biophys. Chem., 1999, 79, 63-79. (Pubitemid 29246093)
95. Ferguson, C.N.; Benchaar, S.A.; Miao, Z.; Loo, J.A.; Chen, H. Direct ionization of large proteins and protein complexes by desorption electrospray ionization-mass spectrometry. Anal. Chem., 2011, 83, 6468-6473.
96. Kitova, E.N.; Soya, N.; Klassen, J.S. Identifying specific small-molecule interactions using electrospray ionization mass spectrometry. Anal. Chem., 2011, 83, 5160-5167.
97. Nettleton, E.J.; Sunde, M.; Lai, Z.H.; Kelly, J.W.; Dobson, C.M.; and Robinson, C.V. Protein subunit interactions and structural integrity of amyloidogenic transthyretins: Evidence from electrospray mass spectrometry. J. Mol. Biol., 1998, 281, 553-564. (Pubitemid 28372131)
98. Rostom, A.A.; Sunde,M.; Richardson, S.J.; Schreiber,G.; Jarvis, S.; Bateman, R.; Dobson, C.M.; and Robinson, C.V. (1998). Dissection of multiprotein complexes using mass spectrometry subunit interactions in transthyretin and retinol-binding protein complexes. Proteins, 1998, Suppl. 2, 3-11. (Pubitemid 28547514)
99. McCammon, M.G.; Scott, D.J.; Keetch, C.A.; Greene, L.H.; Purkey, H.E.; Petrassi, M.; Kelly, J.W.; Robinson, C.V. Screening transthyretin amyloid fibril inhibitors: Characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure, 2002, 10, 851-863. (Pubitemid 34628713)
100. Almeida, M.R.; Damas, A.M.; Lans, M.C.; Brouwer, A.; Saraiva, M. J. (1997). Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine, 1997, 6, 309-315. (Pubitemid 27431403)
101. Lans, M.C.; Klasson-Wehler, E.; Willemsen, M.; Meussen, E.; Safe, S.; Brouwer, A. Structure-dependent, competitive interaction of hydroxypolychlorobiphenyls, o-dibenzo-p-dioxins and o-dibenzofurans with human transthyretin. Chem. Biol. Interact., 1993, 88, 7-21. (Pubitemid 23205415)
102. Almeida, M.R.; Macedo, B.; Cardoso, I.; Alves, I.; Valencia, G.; Arsequell, G.; Planas, A.; Saraiva, M.J. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J., 2004, 381, 351-356. (Pubitemid 38969677)
103. Marchesini, G.R.; Meulenberg, E.; Haasnoot, W.; Mizuguchi, M.; Irth, H. Recognition of Thyroid-Disrupting Chemicals Using Transport Proteins. Anal. Chem., 2006, 78, 1107-1114. (Pubitemid 43271840)
104. Marchesini, G.R.; Meimaridou, A.; Haasnoot, W.; Meulenberg, E.; Albertus, F.; Mizuguchi, M.; Takeuchi, M.; Irth, H.; Murk, A.J. Biosensor discovery of thyroxine transport disrupting chemicals. Toxicol. Appl. Pharmacol., 2008, 232, 150-160.
105. Choi, S.; Connelly, S.; Reixach, N.; Wilson, I. A.; Kelly, J. W. Chemoselective small molecules that covalently modify one lysine in a nonenzyme protein in plasma. Nat. Chem. Biol., 2010, 6, 133-139.
106. Choi, S.; Reixach, N.; Connelly, S.; Johnson, S.M.; Wilson, I.A.; Kelly, J.W. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J. Am. Chem. Soc., 2010, 132, 1359-1370.
107. Kelly, J.W.; Choi, S. Small molecules that covalently modify transthyretin. US Patent 2010/052672, June 23, 2011. (WO 2011075210 A2
108. Choi, S.; Kelly, J.W. A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorg. Med. Chem., 2011, 19, 1505-1514.
109. Burke, T.J.; Loniello, K.R.; Beebe, J.A.; Ervin, K.M. Development and application of fluorescence polarization assays in drug discovery. Comb. Chem. High Throughput Screen., 2003, 6, 183-194. (Pubitemid 36514198)
110. Huang, X.; Aulabaugh, A. Application of fluorescence polarization in HTS assays. Methods Mol. Biol., 2009, 565, 127-143.
111. Saraiva, M.J.M.; Costa, P.P.; Goodman, D.S. Transthyretin (prealbumin) in familial amyloidotic polyneuropathy: Genetic and functional aspects. Adv. Neurol., 1988, 48, 189-200.
112. Purkey, H.E.; Dorrell, M.I.; Kelly, J.W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. U S A., 2001, 98, 5566-5571. (Pubitemid 32435682)
113. McCutchen, S.L.; Colon, W.; Kelly, J.W. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry, 1993, 32, 12119-12127. (Pubitemid 23353652)
114. Hammarström, P.; Wiseman, R.L.; Powers, E.T., Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science, 2003, 299, 713-716. (Pubitemid 36159487)
115. Connors LH, Ericsson T, Skare J, Jones LA, Lewis WD, Skinner M. A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing. Biochim. Biophys. Acta, 1998, 1407, 185-192. (Pubitemid 29067435)
116. Alves, I.L.; Hayes, M.T.; Saraiva, M.J. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur. J. Biochem., 1997, 249, 662-668. (Pubitemid 27479035)
117. Altland, K.; Rauh, S.; Hacker, R. Demonstration of human prealbumin by double one-dimensional slab gel electrophoresis. Electrophoresis, 1981, 2, 148-155. (Pubitemid 11003285)
118. Ferreira, N.; Cardoso, I.; Domingues, M.R.; Vitorino, R.; Bastos, M.; Bai, G.; Saraiva, M.J.; Almeida, M.R. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett., 2009, 583, 3569-3576.
119. Ferreira, N.; Saraiva, M.J.; Almeida, M.R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett., 2011, 585, 2424-2430.
120. Shnyrov, V.L.; Villar, E.; Zhadan, G.G.; Sanchez-Ruiz, J.M.; Quintas, A.; Saraiva, M.J.; Brito, R.M. Comparative calorimetric study of nonamyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophys. Chem., 2000, 88, 61-67.
121. Takeuchi, M.; Mizuguchi, M.; Kouno, T.; Shinohara, Y.; Aizawa, T.; Demura, M.; Mori, Y.; Shinoda, H.; Kawano, K. Destabilization of transthyretin by pathogenic mutations in the DE loop. Proteins, 2007, 66, 716-725. (Pubitemid 46106776)
122. Kolstoe, S.E.; Mangione, P.P.; Bellotti, V.; Taylor, G.W.; Tennent, G.A.; Deroo, S.; Morrison, A.J.; Cobb, A.J.; Coyne, A.; McCammon, M.G.; Warner, T.D.; Mitchell, J.; Gill, R.; Smith, M.D.; Ley, S.V.; Robinson, C.V.; Wood, S.P.; Pepys, M.B. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc. Natl. Acad. Sci. U S A., 2010, 107, 20483-20488.
123. Kepp, O.; Galluzzi, L.; Lipinski, M.; Yuan, J.; Kroemer, G. Cell death assays for drug discovery. Nat. Rev. Drug Discov., 2011, 10, 221-237.
124. Cardoso, I.; Almeida, M.R.; Ferreira, N.; Arsequell, G.; Valencia, G.; Saraiva, M.J. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochem. J., 2007, 408, 131-138. (Pubitemid 350158411)
125. Nerelius, C.; Johansson, J.; Sandegren, A. Amyloid beta-peptide aggregation. What does it result in and how can it be prevented? Front Biosci., 2009, 14, 1716-1729.
126. Zraika, S.; Hull, R.L.; Verchere, C.B.; Clark, A.; Potter, K.J.; Fraser, P.E.; Raleigh, D.P.; Kahn, S.E. Toxic oligomers and islet beta cell death: Guilty by association or convicted by circumstantial evidence?. Diabetologia, 2010, 53, 1046-1056.
127. Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J.W.; Buxbaum, J.N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture, Proc. Natl. Acad. Sci. USA, 2004, 101, 2817-2822. (Pubitemid 38327694)
128. Reixach, N.; Adamski-Werner, S.L.; Kelly, J.W.; Koziol, J.; Buxbaum, J.N. Cell based screening of inhibitors of transthyretin aggregation. Biochem. Biophys. Res. Commun., 2006, 348, 889-897. (Pubitemid 44233502)
129. Bourgault, S.; Choi, S.; Buxbaum, J.N.; Kelly, J.W.; Price, J.L.; Reixach, N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res. Commun., 2011, 410, 707-713.
130. Crook, Z.R.; Housman, D. Huntington's disease: Can mice lead the way to treatment? Neuron, 2011, 69, 423-435.
131. Dawson, T.M.; Ko, H.S.; Dawson, V.L. Genetic animal models of Parkinson's disease. Neuron, 2010, 66, 646-661.
132. Chin, J. Selecting a mouse model of Alzheimer's disease. Methods Mol. Biol. 2011, 670, 169-189.
133. Wadsworth, J.D.; Asante, E.A.; Collinge, J. Review: Contribution of transgenic models to understanding human prion disease. Neuropathol. Appl. Neurobiol. 2010, 36, 576-597.
134. Araki, S.; Shigehiro, Y.; Murakami, T.; Watanabe, S.; Ikegawa, S.; Takahashi, K.; Yamamura, K. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (met30) gene. Mol. Neurobiol., 1994, 8, 15-23.
135. Yi, S.; Takahashi, K.; Naito, M.; Tashiro, F.; Wakasugi, S.; Maeda, S.; Shimada, K.; Yamamura, K.; Araki, S. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am. J. Pathol., 1991, 138, 403-412.
136. Kohno, K.; Palha, J.A.; Miyakawa, K.; Saraiva, M.J.; Ito, S.; Mabuchi, T.; Blaner, W.S.; Iijima, H.; Tsukahara, S.; Episkopou, V.; Gottesman, M.E.; Shimada, K.; Takahashi, K.; Yamamura, K.; Maeda, S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am. J. Pathol., 1997, 150, 1497-1508. (Pubitemid 27152666)
137. Sousa, M.M.; Fernandes, R.; Palha, J.A.; Taboada, A.; Vieira, P.; Saraiva, M.J. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am. J. Pathol., 2002, 161, 1935-1948. (Pubitemid 35265550)
138. Cardoso, I.; Saraiva, M.J. Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB J., 2006, 20, 234-239. (Pubitemid 44933170)
139. Cardoso, I.; Martins, D.; Ribeiro, T.; Merlini, G.; Saraiva, M.J. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: Studies in FAP mouse models. J. Transl. Med., 2010, 8, 74.
140. Santos, S.D.; Fernandes, R.; Saraiva, M.J.; The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol. Aging, 2010, 31, 280-289.
141. Berg, I.; Thor, S.; Hammarström, P. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster. Neurodegener. Dis. 2009, 6, 127-138.
142. Pokrzywa, M.; Dacklin, I.; Hultmark, D.; Lundgren, E. Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. Eur J Neurosci., 2007, 26, 913-924. (Pubitemid 47274622)
143. Pokrzywa, M.; Dacklin, I; Vestling, M.; Hultmark, D.; Lundgren, E.; Cantera, R. Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis. PLoS One., 2010, 5(12):e14343.
144. Noborn, F.; O'Callaghan. P.; Hermansson, E.; Zhang, X.; Ancsin, J.B.; Damas, A.M.; Dacklin, I.; Presto, J.; Johansson, J.; Saraiva, M.J.; Lundgren, E.; Kisilevsky, R.; Westermark, P.; Li, J.P. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc. Natl. Acad. Sci. U S A., 2011, 108, 5584-5589.
145. Ueda, M.; Ageyama, N.; Nakamura, S.; Nakamura, M.; Chambers, J.K.; Misumi, Y.; Mizuguchi, M.; Shinriki, S.; Kawahara, S.; Tasaki, M.; Jono, H.; Obayashi, K.; Sasaki, E.; Une, Y.; Ando, Y. Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: A valid pathological model of the human disease. Lab. Invest., 2011. DOI: 10.1038/labinvest.2011.195.
146. Tang, Y.T.; Marshall, G.R. Virtual screening for lead discovery. Methods Mol. Biol., 2011, 716, 1-22.
147. Badrinarayan, P.; Sastry, GN. Virtual High-throughput Screening in New Lead Identification. Comb. Chem. High Throughput Screen., 2011, 14, 840-860.
148. Kapetanovic, M.; Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chem. Biol. Interact., 2008, 171, 165-176.
149. Simões, C.J.; Mukherjee, T.; Brito, R.M.; Jackson, R.M. Toward the discovery of functional transthyretin amyloid inhibitors: Application of virtual screening methods. J. Chem. Inf. Model., 2010, 50, 1806-1820.
150. Sardana, D.; Zhu, C.; Zhang, M.; Gudivada, R.C.; Yang, L.; Jegga, A.G. Drug repositioning for orphan diseases. Brief Bioinform., 2011, 12, 346-356.
151. Coté, T.R.; Xu, K.; Pariser, A.R. Accelerating orphan drug development. Nat. Rev. Drug Discov., 2010, 9, 901-902.
152. Dunoyer, M. Accelerating access to treatments for rare diseases. Nat. Rev. Drug Discov., 2011, 10, 475-476.
153. Kolstoe, S.E.; Wood, S.P. Drug targets for amyloidosis. Biochem. Soc. Trans., 2010, 38, 466-470.
154. Pepys, M.B.; Herbert, J.; Hutchinson, W.L.; Tennent, G.A.; Lachmann, H.J.; Gallimore, J.R.; Lovat, L.B.; Bartfai, T.; Alanine, A.; Hertel, C.; Hoffmann, T.; Jakob-Roetne, R.; Norcross, R.D.; Kemp, J.A.; Yamamura, K.; Suzuki, M.; Taylor, G.W.; Murray, S.; Thompson, D.; Purvis, A.; Kolstoe, S.; Wood, S.P.; Hawkins, P.N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 2002, 417, 254-259. (Pubitemid 34534701)
155. Kolstoe, S.E.; Ridha, B.H.; Bellotti, V.; Wang, N.; Robinson, C.V.; Crutch, S.J.; Keir, G.; Kukkastenvehmas, R.; Gallimore, J.R.; Hutchinson, W.L.; Hawkins, P.N.; Wood, S.P.; Rossor, M.N.; Pepys, M.B. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl, Acad. Sci. U S A., 2009, 106, 7619-7623.
156. Bodin, K; Ellmerich, S.; Kahan, M.C.; Tennent, G.A.; Loesch, A.; Gilbertson, J.A.; Hutchinson, W.L.; Mangione, P.P.; Gallimore, J.R.; Millar, D.J.; Minogue, S.; Dhillon, A.P.; Taylor, G.W.; Bradwell, A.R.; Petrie, A.; Gillmore, J.D.; Bellotti, V.; Botto, M.; Hawkins, P.N.; Pepys, M.B. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 2010, 468, 93-97.
157. Gillmore, J.D.; Tennent, G.A.; Hutchinson, W.L.; Gallimore, J.R.; Lachmann, H.J.; Goodman, H.J.; Offer, M.; Millar, D.J.; Petrie, A.; Hawkins, P.N.; Pepys, M.B. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br. J. Haematol., 2010, 148, 760-767.